Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 2
1996 3
1999 2
2002 1
2003 2
2006 2
2007 1
2010 1
2011 3
2012 3
2015 2
2016 1
2017 1
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
Yoshida S, Onozawa M, Miyashita N, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Hirabayashi S, Mori A, Hidaka D, Minauchi K, Shigematsu A, Hashiguchi J, Igarashi T, Kakinoki Y, Tsutsumi Y, Ibata M, Kobayashi H, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Ota S, Kondo T, Teshima T. Yoshida S, et al. Int J Hematol. 2023 Apr;117(4):544-552. doi: 10.1007/s12185-022-03522-6. Epub 2022 Dec 26. Int J Hematol. 2023. PMID: 36572814 Free article.
Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients w …
Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.00 …
Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
Kokate P, Sawaimoon S, Bhatia S, Mandava S. Kokate P, et al. Genet Test Mol Biomarkers. 2012 Apr;16(4):239-45. doi: 10.1089/gtmb.2011.0125. Epub 2011 Oct 24. Genet Test Mol Biomarkers. 2012. PMID: 22023243
A majority of the discordant cases within the IHC negative (score 0 and 1) and IHC positive (score 3) were high-grade tumors. Polysomy 17 and monosomy 17 was seen in 7.3% of the total cases of each. Furthermore, a majority of FISH positive cases were noted in Intrad …
A majority of the discordant cases within the IHC negative (score 0 and 1) and IHC positive (score 3) were high-grade tumors. Polysomy 17 an …
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.
Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV. Greenberg AJ, et al. Blood Cancer J. 2015 Jan 2;5(1):e271. doi: 10.1038/bcj.2014.91. Blood Cancer J. 2015. PMID: 25555162 Free PMC article.
We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing resu …
We examined four clinically assessed cytogenetic subtypes (t(11;14), t(4;14), monosomy 13/del13q and monosomy 17/del17p in 292 …
Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease.
Garcia J, Duran A, Tabernero MD, Garcia Plaza A, Flores Corral T, Najera ML, Gomez-Alonso A, Orfao A. Garcia J, et al. Cytometry B Clin Cytom. 2003 Jan;51(1):14-20. doi: 10.1002/cyto.b.10006. Cytometry B Clin Cytom. 2003. PMID: 12500293 Free article.
From a clinical point of view, numerical abnormalities of chromosome 17, especially monosomy 17, were associated with a significantly higher incidence of rectal tumors (P = 0.001) and Dukes' stage D (P = 0.02) and a lower median of disease-free survival among patien …
From a clinical point of view, numerical abnormalities of chromosome 17, especially monosomy 17, were associated with a signif …
Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.
Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH. Put N, et al. Ann Hematol. 2012 Jun;91(6):863-73. doi: 10.1007/s00277-011-1393-y. Epub 2011 Dec 30. Ann Hematol. 2012. PMID: 22205151
MYC translocations were frequently observed with concomitant adverse cytogenetic markers, such as del(11q) (n = 8/30) and/or del(17p)/monosomy 17 (n = 7/30). In addition, the presence of unbalanced translocations (n = 24 in 13/30 cases) and complex karyotype (n = 16 …
MYC translocations were frequently observed with concomitant adverse cytogenetic markers, such as del(11q) (n = 8/30) and/or del(17p)/mon …
Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma.
Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Brown JA, et al. J Urol. 1994 Oct;152(4):1157-62. doi: 10.1016/s0022-5347(17)32527-2. J Urol. 1994. PMID: 8072085 Review.
Chromosomes 4, 6, and X were never aneusomic. The percentage of monosomy 17 nuclei was 2 to 4 times the amount noted with the other autosomes for tumor and benign tissue. ...
Chromosomes 4, 6, and X were never aneusomic. The percentage of monosomy 17 nuclei was 2 to 4 times the amount noted with the …
Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb HB, Singhal D, Cibich A, Bardy P, Kok CH, Hiwase DK, Shah MV. Baranwal A, et al. Bone Marrow Transplant. 2023 Jul;58(7):769-776. doi: 10.1038/s41409-023-01970-0. Epub 2023 Apr 3. Bone Marrow Transplant. 2023. PMID: 37012415
In t-MDS, the presence of monosomy 5 (HR 3.63, P = 0.006) or monosomy 17 (HR 11.81, P = 0.01) pre-alloSCT were associated with higher RI. ...
In t-MDS, the presence of monosomy 5 (HR 3.63, P = 0.006) or monosomy 17 (HR 11.81, P = 0.01) pre-alloSCT were associated with …
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, Hale CL, Parr L, Lynn M, Sammartino G, Lukacs JL, Stein C, Bailey C, Zangari M, Davies FE, Van Rhee F, Barlogie B, Morgan GJ. Sawyer JR, et al. Leukemia. 2017 Mar;31(3):637-644. doi: 10.1038/leu.2016.253. Epub 2016 Oct 3. Leukemia. 2017. PMID: 27694925 Free PMC article.
Analysis of clones utilizing interphase fluorescence in situ hybridization (iFISH), metaphase FISH and spectral karyotyping identified either monosomy 17 or del17p in all patients. Amplification of 1q21 was identified in eight patients, demonstrating an additional h …
Analysis of clones utilizing interphase fluorescence in situ hybridization (iFISH), metaphase FISH and spectral karyotyping identified eithe …
The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM, Coriu D, Arion C, Colita A, Jardan C. Crisan AM, et al. J Med Life. 2015 Oct-Dec;8(4):502-8. J Med Life. 2015. PMID: 26664479 Free PMC article.
ABBREVIATIONS: CML = Chronic Myeloid Leukemia, BCR-ABL1 = Break Cluster Region - Abelson gene, TKI = tyrosine kinase inhibitor treatment, ACAs = additional cytogenetic abnormalities, CCyR = complete cytogenetic response, PCyR = partial cytogenetic response, mCyR = minor cytogenet …
ABBREVIATIONS: CML = Chronic Myeloid Leukemia, BCR-ABL1 = Break Cluster Region - Abelson gene, TKI = tyrosine kinase inhibitor treatment, AC …
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q, Zhao D, Zarif M, Davidson MB, Minden MD, Tierens A, Yeung YWT, Wei C, Chang H. Zhou Q, et al. Blood Adv. 2024 Apr 9;8(7):1760-1771. doi: 10.1182/bloodadvances.2023011869. Blood Adv. 2024. PMID: 38286462 Free PMC article.
The clinicopathological features were largely similar, irrespective of the classification used, except for higher rates of complex karyotype, monosomy 17, TP53 mutations, and fewer RUNX1 mutations in the WHO-AML-MR group. ...
The clinicopathological features were largely similar, irrespective of the classification used, except for higher rates of complex karyotype …
25 results